"Head and Neck Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
| Descriptor ID |
D006258
|
| MeSH Number(s) |
C04.588.443
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Head and Neck Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Head and Neck Neoplasms".
This graph shows the total number of publications written about "Head and Neck Neoplasms" by people in this website by year, and whether "Head and Neck Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 7 | 1 | 8 |
| 1997 | 3 | 1 | 4 |
| 1998 | 6 | 0 | 6 |
| 1999 | 13 | 1 | 14 |
| 2000 | 14 | 1 | 15 |
| 2001 | 8 | 3 | 11 |
| 2002 | 8 | 0 | 8 |
| 2003 | 12 | 1 | 13 |
| 2004 | 16 | 1 | 17 |
| 2005 | 13 | 1 | 14 |
| 2006 | 14 | 1 | 15 |
| 2007 | 15 | 2 | 17 |
| 2008 | 17 | 1 | 18 |
| 2009 | 19 | 1 | 20 |
| 2010 | 15 | 4 | 19 |
| 2011 | 15 | 1 | 16 |
| 2012 | 14 | 1 | 15 |
| 2013 | 12 | 2 | 14 |
| 2014 | 32 | 2 | 34 |
| 2015 | 22 | 2 | 24 |
| 2016 | 27 | 3 | 30 |
| 2017 | 23 | 1 | 24 |
| 2018 | 18 | 5 | 23 |
| 2019 | 23 | 2 | 25 |
| 2020 | 19 | 0 | 19 |
| 2021 | 21 | 1 | 22 |
| 2022 | 19 | 0 | 19 |
| 2023 | 21 | 1 | 22 |
| 2024 | 6 | 3 | 9 |
| 2025 | 9 | 0 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Head and Neck Neoplasms" by people in Profiles.
-
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study. J Clin Oncol. 2025 Oct 10; 43(29):3209-3220.
-
Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. J Immunother Cancer. 2025 Aug 24; 13(8).
-
LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC. Future Oncol. 2025 Jul; 21(16):2007-2016.
-
Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2025 May 01; 11(5):492-501.
-
Patient-specific modeling of radiation-induced lymphopenia for head and neck cancer. Med Phys. 2025 Jun; 52(6):3583-3594.
-
Anti-PD1 prolongs the response of PI3K and farnesyl transferase inhibition in HRAS- and PIK3CA-mutant head and neck cancers. Neoplasia. 2025 05; 63:101157.
-
Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas. Oral Oncol. 2025 Apr; 163:107207.
-
NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025. J Natl Compr Canc Netw. 2025 02; 23(2):2-11.
-
Immunotherapy in Head and Neck Cancer. Cancer Treat Res. 2025; 129:119-156.
-
Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT study. J Immunother Cancer. 2024 Nov 03; 12(11).